← Evidence map

ArticleEuropean journal of cancer (Oxford, England : 1990)2017

Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].

Christophe Massard et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44]. | OpenQuestion